CTHRC1 Antibody (Antigen Affinity Purified)

CTHRC1 Antibody Datasheet

CTHRC1 Antibody Product Information

• Immunogen: Recombinant Human CTHRC1 protein (Catalog#11647-H08H)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Human CTHRC1 (rh CTHRC1; Catalog#11647-H08H; NP_612464.1; Met 1-Lys 243). CTHRC1 specific IgG was purified by Human CTHRC1 affinity chromatography.

CTHRC1 Antibody Usage Guide

• Specificity: Human CTHRC1
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CTHRC1 in WB. Using a DAB detection system, the detection limit for Human CTHRC1 is approximately 4 ng/lane under non-reducing conditions and reducing conditions.
• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CTHRC1. The detection limit for Human CTHRC1 is approximately 0.00245 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

CTHRC1 Antibody Background

Collagen triple helix repeat-containing protein 1, also known as Protein NMTC1, and CTHRC1, is a secreted protein that is glycosylated and highly conserved from lower chordates to mammals. CTHRC1 expression was not detectable in normal arteries. However, on injury it was transiently expressed by fibroblasts of the remodeling adventitia and by smooth muscle cells of the neointima. It was also found in the matrix of calcifying human atherosclerotic plaques. A short collagen motif with 12 Gly-X-Y repeats appears to be responsible for trimerization of the CTHRC1 protein and this renders the molecule susceptible to cleavage by collagenase. CTHRC1 overexpression caused a dramatic reduction in collagen type I mRNA and protein levels. CTHRC1 has many novel biochemical activities. It is the downstream target of bone morphogenetic protein-2 (BMP-2) in osteochondroprogenitor-like cells. CTHRC1 increases bone mass as a positive regulator of osteoblastic bone formation and offers an anabolic approach for the treatment of osteoporosis. CTHRC1 expression in vascular cells regulates transforming growth factor beta responsiveness, thereby impacting transforming growth factor beta target genes, including collagens. The ability of CTHRC1 to reduce collagen deposition by inhibition of Smad2/3 activation could have major clinical applications in the fields of vascular disease, repair, and fibrosis.

References

1. Pyagay,P. et al., 2005,Circ Res. 96 (2): 261-8.
2. LeClair, R. et al., 2007, Trends Cardiovasc Med. 17 (6): 202-5.
3. Kimura, H. et al., 2008, PLoS One. 3 (9): e3174.
4. Leclair, RJ. et al., 2008, Arterioscler Thromb Vasc Biol. 28 (7): 1332-8.